<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet type="text/xsl" href="static/style.xsl"?><OAI-PMH xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd"><responseDate>2026-04-17T12:07:01Z</responseDate><request verb="GetRecord" identifier="oai:riubu.ubu.es:10259/7561" metadataPrefix="qdc">https://riubu.ubu.es/oai/request</request><GetRecord><record><header><identifier>oai:riubu.ubu.es:10259/7561</identifier><datestamp>2023-04-19T08:00:45Z</datestamp><setSpec>com_10259_4365</setSpec><setSpec>com_10259_5086</setSpec><setSpec>com_10259_2604</setSpec><setSpec>com_10259_4363</setSpec><setSpec>com_10259_6185</setSpec><setSpec>com_10259_3591</setSpec><setSpec>com_10259.4_106</setSpec><setSpec>col_10259_4366</setSpec><setSpec>col_10259_4364</setSpec><setSpec>col_10259_6186</setSpec></header><metadata><qdc:qualifieddc xmlns:qdc="http://dspace.org/qualifieddc/" xmlns:doc="http://www.lyncode.com/xoai" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:dc="http://purl.org/dc/elements/1.1/" xsi:schemaLocation="http://purl.org/dc/elements/1.1/ http://dublincore.org/schemas/xmls/qdc/2006/01/06/dc.xsd http://purl.org/dc/terms/ http://dublincore.org/schemas/xmls/qdc/2006/01/06/dcterms.xsd http://dspace.org/qualifieddc/ http://www.ukoln.ac.uk/metadata/dcmi/xmlschema/qualifieddc.xsd">
<dc:title>Targets, Mechanisms and Cytotoxicity of Half-Sandwich Ir(III) Complexes Are Modulated by Structural Modifications on the Benzazole Ancillary Ligand</dc:title>
<dc:creator>Acuña, M. Isabel</dc:creator>
<dc:creator>Rubio Antolin, Ana Rosa</dc:creator>
<dc:creator>Martínez Alonso, Marta</dc:creator>
<dc:creator>Busto Vázquez, Natalia</dc:creator>
<dc:creator>Rodríguez, Ana María</dc:creator>
<dc:creator>Davila Ferreira, Nerea</dc:creator>
<dc:creator>Smythe, Carl</dc:creator>
<dc:creator>Espino Ordóñez, Gustavo</dc:creator>
<dc:creator>García Ruiz, Begoña</dc:creator>
<dc:creator>Domínguez, Fernando</dc:creator>
<dc:subject>Organometallic iridium complex</dc:subject>
<dc:subject>DNA binding</dc:subject>
<dc:subject>Mitochondrial damage</dc:subject>
<dc:subject>Proton leak</dc:subject>
<dc:subject>Apoptosis</dc:subject>
<dcterms:abstract>Cancers are driven by multiple genetic mutations but evolve to evade treatments targeting&#xd;
specific mutations. Nonetheless, cancers cannot evade a treatment that targets mitochondria, which&#xd;
are essential for tumor progression. Iridium complexes have shown anticancer properties, but&#xd;
they lack specificity for their intracellular targets, leading to undesirable side effects. Herein we&#xd;
present a systematic study on structure-activity relationships of eight arylbenzazole-based Iridium(III)&#xd;
complexes of type [IrCl(Cp*)], that have revealed the role of each atom of the ancillary ligand in the&#xd;
physical chemistry properties, cytotoxicity and mechanism of biological action. Neutral complexes,&#xd;
especially those bearing phenylbenzimidazole (HL1 and HL2), restrict the binding to DNA and&#xd;
albumin. One of them, complex 1[C,NH-Cl], is the most selective one, does not bind DNA, targets&#xd;
exclusively the mitochondria, disturbs the mitochondria membrane permeability inducing proton&#xd;
leak and increases ROS levels, triggering the molecular machinery of regulated cell death. In&#xd;
mice with orthotopic lung tumors, the administration of complex 1[C,NH-Cl] reduced the tumor&#xd;
burden. Cancers are more vulnerable than normal tissues to a treatment that harnesses mitochondrial&#xd;
dysfunction. Thus, complex 1[C,NH-Cl] characterization opens the way to the development of new&#xd;
compounds to exploit this vulnerability</dcterms:abstract>
<dcterms:dateAccepted>2023-03-20T10:47:17Z</dcterms:dateAccepted>
<dcterms:available>2023-03-20T10:47:17Z</dcterms:available>
<dcterms:created>2023-03-20T10:47:17Z</dcterms:created>
<dcterms:issued>2022-12</dcterms:issued>
<dc:type>info:eu-repo/semantics/article</dc:type>
<dc:identifier>http://hdl.handle.net/10259/7561</dc:identifier>
<dc:identifier>10.3390/cancers15010107</dc:identifier>
<dc:identifier>2072-6694</dc:identifier>
<dc:language>eng</dc:language>
<dc:relation>Cancers. 2022, V. 15, n. 1, 107</dc:relation>
<dc:relation>https://doi.org/10.3390/cancers15010107</dc:relation>
<dc:relation>info:eu-repo/grantAgreement/Fundación Bancaria Caixa d'Estalvis i Pensions de Barcelona//LCF%2FPR%2FPR12%2F11070003//</dc:relation>
<dc:relation>info:eu-repo/grantAgreement/AEI/Plan Estatal de Investigación Científica y Técnica y de Innovación 2017-2020/RTI2018-102040-B-I00/ES/PROPIEDADES ANTIMICROBIANAS DE NUEVOS COMPLEJOS ORGANOMETALICOS/</dc:relation>
<dc:relation>info:eu-repo/grantAgreement/Junta de Castilla y León//BU305P18//DISEÑO Y CARACTERIZACIÓN DE COMPLEJOS BIOINORGÁNICOS Y CLÚSTERES CUÁNTICOS ATÓMICOS. PROPIEDADES ANTIMICROBIANAS EN CEPAS RESISTENTES. PROPIEDADES ANTITUMORALES EN LA OSCURIDAD Y BAJO IRRADIACIÓN/</dc:relation>
<dc:relation>info:eu-repo/grantAgreement/COST//CA18202/EU/Network for Equilibria and Chemical Thermodynamics Advanced Research/NECTAR/</dc:relation>
<dc:rights>http://creativecommons.org/licenses/by/4.0/</dc:rights>
<dc:rights>info:eu-repo/semantics/openAccess</dc:rights>
<dc:rights>Atribución 4.0 Internacional</dc:rights>
<dc:publisher>MDPI</dc:publisher>
</qdc:qualifieddc></metadata></record></GetRecord></OAI-PMH>